News

Your tasks: 

• Collaboration in the Healthcare Hub Berlin team
• Research and analysis of current trends in the German healthcare sector, especially in the field of DVG/DiGA 
• Collaboration on cross-divisional innovation projects and startup cooperations  
• Collaboration on the communication concept as well as participation in the creation of corresponding materials  
• Screening of relevant startups in the area of digital health – "offline" and at startup events and conferences  
• Representation of Pfizer in the Berlin startup scene  
• Support in the preparation and implementation of events in the field of digital health, startups and eHealth

Your profile:  

• You are at an advanced stage of your studies with a business, economics or technical focus; preferably with a focus on health economics/health management, digitalization or innovation.  
• You have proven experience and/or internships in the field of (digital) healthcare /eHealth and have an affinity for digital technologies as well as creativity methods  
• You enjoy working in a team and also convince with an independent way of working  
• Very good knowledge of the German and English language  

Your working hours will be 20 hours/week during the lecture period. During the lecture-free period you can also work full time. The position is limited to 6 months.

We are looking forward to your application!

Pfizer clinical teams have near real-time clinical and operational treatment-blinded, coded data access via multiple clinical data electronic systems. By taking in and mining data from these systems Pfizer Global Product Development wants to identify potential trends and patterns which could generate clinical hypotheses that drive earlier data-driven study decision making towards delivering much needed medicines and vaccines as efficiently as possible.

Are you ready to develop a solution for this challenge? These are the selection criteria: 

• Experience and understanding of the challenge statement(s) and experience in healthcare and/or clinical trial data markets where this solution could be used 
• Prior experience with Machine Learning and NLP is a must 
• Solution must be compliant with all applicable legal, privacy, and regulatory requirements 
• Differentiation of solution within the digital technology landscape 
• Solution must be scalable across protocols and therapeutic areas in clinical development programs 
• Cost-effectiveness (to scale and to use) 
• Capability of successful applicant to develop and demonstrate the solution for future (near-term) global use. 

Applications are accepted through Jan 07, 2022.

Please share this challenge with companies that you think may be a good fit! 

"Currently, 24 DiGAs are listed in the directory. For some, that's a sobering number; for others, it's just the beginning of a promising development. At Pfizer, we see great potential in the adoption of DiGAs and think DiGAs will be an integral part of care in the future," Alipiev said. 

Why are DiGAs so slow to develop? 

The legal basis for DiGAs was already established in November 2019 with the Digital Care Act. But why do DiGAs still hardly play a role in the everyday lives of patients and physicians? Ekaterina Alipiev sees one of the reasons in the lack of experience in the approval and marketing of medical devices: "Currently, many startups are working on the development of new DiGAs. They are able to act quickly and agilely and usually have a high level of IT expertise. However, they often lack experience in medical device approval or commercialization," Alipiev said. However, DiGA approval applications are complex.  

Win-win: startegic cooperations between Pfizer and startups  

This is where cooperation between Pfizer and startups comes in handy: "Pfizer benefits from the startups' innovative ideas and agile structure. In return, the Pfizer team supports the founders with advice and provides infrastructure or access to target groups. "  

The team around Ekaterina Alipiev at the Pfizer Healtcare Hub Berlin and Pfizer's experts from Market Access and Medical support DiGA manufacturers with their expertise, experience and a broad network in all challenges around the market launch of a DiGA: for example, in the approval process, in the development of market approval or pricing strategies.

More about our services for DiGA startups

On Monday, Dr. Hans Zebner participated in a panel discussion on innovations in Green & Sustainable Manufacturing at the Manufacturing themed session at the Zwick/Roell AG Innovation Center in Ulm: Where to start everywhere in the various sectors and why is it worthwhile to fully exploit this potential much more consistently? Despite all the optimism, here in Germany we need to be much faster in implementing them. 

The second day of the event started with tech breakfasts: at the Tech Breakfast "Competitiveness through collaboration: How companies across industries collaborate in the innovation process", Peter Neske, together with Fatma Karatay from TransnetBW GmbH and Christian Bell as host of iteratec GmbH Stuttgart, presented the results of a year-long Blue Ocean working group at bwcon on whether and how innovations can be measured. Peter Neske also discussed sustainability and digital trends with former CyberOne Award winners in the "Green, Digital & Life Science" panel.

Today, the last day of the event, Peter Neske, together with Claudia Roth, Vetter GmbH, will lead through the Medicine themed session at the newly opened CUBEX ONE in Mannheim, where the focus will be on DiGAs, among others: How can DiGAs find their place in everyday patient care? In addition, innovations from the life science sector will be presented by exciting speakers using various examples. It's worth a visit: The event starts at 2 p.m. live in Mannheim, and there will also be a livestream.